Recovery From Paranoia: a Qualitative Exploration

Paranoia Clinical Trial

Official title:

Recovery From Paranoia: a Qualitative Exploration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04824781
• Other study ID #: PID 15402
• Secondary ID: HRAIRAS
• Status: Completed
• Start date: June 9, 2021
• Est. completion date: February 16, 2022

Study information

• Verified date: March 2021
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Paranoia, the experience of undue or excessive mistrust, exists on a continuum which includes suspicious thoughts, ideas of reference, and persecutory delusions. Persecutory delusions refers to strong unfounded fears that others intend harm. These fears are very common. They affect around 70% of patients with schizophrenia. They can be distressing and make day-to-day tasks difficult. However, current treatments are limited and a significant proportion of people do not benefit sufficiently. Therefore, improvements in treatment are needed. A better understanding of the experience of recovery from paranoia will help inform theoretical understanding and treatment development. Currently we do not fully understand what causes paranoia to occur, persist, or end. As such, it is critical to understand the experiences of those who have recovered, in particular what elements encourage recovery. Therefore, the aim of this study is to gain a first-person perspective on how people recover from paranoia and what psychological processes are important for recovery from paranoia. Using a qualitative approach appropriate for exploratory research, semi-structured interviews will be conducted with 12-15 patients who have recovered from paranoia. Interviews will be analysed using interpretative phenomenological analysis, a qualitative research approach which aims to provide insight on how an individual, in a particular situation, makes sense of their experience.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: February 16, 2022
• Est. primary completion date: July 27, 2021
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Participant has recovered from the paranoia. This is defined as: A.) conviction in persecution beliefs is rated as less than 10% and B.) not experiencing significant distress related to paranoia and C.) currently scoring outside the clinical range of the revised Green et al., Paranoid Thoughts Scale (R-GPTS; Freeman, 2019);
• Participants should have had experiences of paranoia in the context of non-affective psychosis. This will be determined by participant's agreement that they previously had the sort of thoughts listed in the revised Green et al. Paranoid Thoughts Scale (R-GPTS; Freeman, 2019);
• Participant is currently a patient of Oxford Health NHS Foundation Trust;
• Participant is willing and able to give informed consent for participation in the study;
• Aged 16 years or above;
• Participant has sufficient English language skills to participate in the interview. Exclusion Criteria: The following exclusion criteria will apply based on concerns regarding risk and capacity

to consent:

• Currently experiencing acute psychiatric symptoms which preclude ability to participate in a sustained interview;
• Diagnosis of a moderate to severe intellectual disability;
• High levels of associated risk to self or to others e.g. actively suicidal;
• Primary diagnosis of alcohol or drug misuse; personality disorder; significant forensic history;
• At the time of recruitment COVID-19 restrictions do not permit face-to-face interviews and the participant is not willing or able to conduct the interview remotely via video call.

Related Conditions & MeSH terms

• Delusions
• Paranoia
• Persecutory Delusion

Intervention

Other:
• Qualitative interview
Participants will be interviewed about their experiences of recovery from paranoia.

Locations

Country	Name	City	State
United Kingdom	Oxford Health NHS Foundation Trust	Oxford	Oxfordshire

Sponsors (1)

Lead Sponsor	Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Qualitative interview accounts	Semi-structured interpretative phenomenological analysis (IPA) interviews will be used.	March 2021-March 2022